United Therapeutics Corporation $UTHR Shares Sold by Swedbank AB

Swedbank AB lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 1.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 324,772 shares of the biotechnology company’s stock after selling 4,346 shares during the quarter. Swedbank AB’s holdings in United Therapeutics were worth $158,245,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Torren Management LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management lifted its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at $31,000. Wilmington Savings Fund Society FSB lifted its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of United Therapeutics during the 4th quarter valued at $48,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.5%

NASDAQ UTHR opened at $568.43 on Friday. The company’s fifty day simple moving average is $563.25 and its 200-day simple moving average is $511.57. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The stock has a market cap of $24.13 billion, a P/E ratio of 20.98, a PEG ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the firm posted $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the topic of several recent research reports. HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $619.42.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 14,440 shares of United Therapeutics stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $472.13, for a total transaction of $6,817,557.20. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 569,913 shares of company stock worth $317,603,631. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.